Home > Haematology > EHA 2020 > Venetoclax + navitoclax promising for R/R ALL or LL

Venetoclax + navitoclax promising for R/R ALL or LL

Venetoclax + navitoclax was well-tolerated without unexpected toxicity and with promising preliminary efficacy in heavily pre-treated patients with relapsed or refractory acute lymphoblastic leukaemia or lymphoblastic lymphoma (R/R B- and T-ALL or LL).

Prof. Elias Jabbour (University of Texas MS Anderson Cancer Centre, USA) presented the phase 1, multicentre, open-label, dose-escalation study [1], addressing the unmet need for new treatment options in R/R ALL and LL. The investigators hypothesised that BCL2 inhibitor venetoclax in combination with low-dose navitoclax (a BCL-XL inhibitor) could improve efficacy while minimising dose-limiting toxicities known to occur with standard-dose navitoclax monotherapy.

Patients (n=47, median age 29 years, median number of prior therapies was 4) received 400 mg venetoclax (weight-adjusted equivalent) daily, together with daily oral navito...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on